Navigation Links
Trial Drug Shows Preliminary Promise Against Ovarian Cancer
Date:8/22/2011

SUNDAY, Aug. 21 (HealthDay News) -- An experimental drug that's shown promise against ovarian cancer caused by mutations in the BRCA1 or BRCA2 genes may also be effective against ovarian cancer not caused by those gene mutations, according to a new study.

Olaparib blocks the activity of a protein called poly ADP ribose polymerase (PARP). Both PARP and BRCA proteins are involved in DNA repair. Clinical trials of olaparib in patients with BRCA 1 and 2 mutations have yielded promising results, the study authors noted.

In the new study, Canadian researchers say they're the first to show that olaparib reduces tumor size in patients with non-hereditary (sporadic) ovarian cancer, which is much more common than BRCA-mutated ovarian cancers.

The phase 2 trial included 65 ovarian cancer patients who received 400 milligrams of olaparib twice daily for four weeks. Measurable tumor shrinkage was seen in 41 percent of patients with BRCA mutations and in 24 percent of those without BRCA mutations, the researchers said.

The study was published online Aug. 21 in The Lancet Oncology.

Side effects were described as mild and included fatigue, nausea, vomiting and decreased appetite, study lead author Karen Gelmon, of the B.C. Cancer Agency in Vancouver, and colleagues said in a news release from the journal.

"This finding not only suggests new therapeutic possibilities for women with this aggressive type of ovarian cancer, but also importantly confirms the hypothesis that subpopulations of patients with common sporadic tumors can be targeted effectively with PARP inhibitor therapy," Dr. Melinda Telli, of Stanford University School of Medicine, wrote in an accompanying editorial.

Another expert agreed. Dr. Stephanie V. Blank is an assistant professor in clinical gynecologic oncology at NYU School of Medicine. She said: "It is extremely exciting that an agent as promising as olaparib can be effective in a broader group of women than had been expected. The next challenge will lie in getting our hands on the drug, which at present is only available for patients on clinical trials."

More information

The American Cancer Society outlines the risk factors for ovarian cancer.

-- Robert Preidt

SOURCES: The Lancet Oncology, news release, Aug. 21, 2011; Stephanie V. Blank, M.D., assistant professor in clinical gynecologic oncology, NYU School of Medicine, New York City


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Superdrug Against Range of Viruses Shows Promise in Animal Trials
2. New TB vaccine enters proof-of-concept trial in people living with HIV
3. ESC announces review of Atrial Fibrillation Guidelines
4. University Hospitals Case Medical Center to begin clinical trial on experimental anti-TB drug
5. New clinical trial to examine medication to treat social withdrawal in Fragile X and autism
6. VOICE study will continue as it considers what action to take after results of 2 trials
7. Covidien supports NOSCAR US multicenter human trial
8. Amrubicin improved response rate and progression-free survival vs. topotecan in Phase III trial
9. Patient Disparities Seen in Lung Cancer Drug Trials
10. Women, elderly, minorities poorly represented in lung cancer drug trial data submitted to US FDA
11. Massage eases low back pain in randomized controlled trial
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Trial Drug Shows Preliminary Promise Against Ovarian Cancer
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Apple ... care services, staged a mock evacuation of the facility as part of a disaster ... Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well as the ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Global Healthcare Management’s ... Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s ... The fun run is geared towards children of all ages; it is a ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the ... danger possible to save lost souls in the Philippines. “The Journey: From the Mountains ... a dedicated teacher of the Bible. She has taught all ages and currently teaches ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest and ... plans to open a flagship location in Covington, LA at 401 N. U.S. Highway ... store next to Office Depot in the Holiday Square shopping center. Its location allows ...
(Date:10/12/2017)... ... 2017 , ... Asante, a nationally recognized health system in ... existing home health joint venture through an agreement, effective October 1, 2017, to ... home health company with Asante, delivering clinically integrated care, for the past eight ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)... -- NDS received FDA 510(k) clearance in May 2017 for its highly ... designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... support the improvement of patient outcomes, procedural efficiency, and the lowering ... ... ...
(Date:10/4/2017)... 4, 2017  South Korean-based healthcare product Development Company ... "cprCUBE" on Kickstarter. The device will educate the user ... with better efficiency compared to the dated and pricey ... on efficacy of the compression for a more informed ... goal to raise $5,000. ...
(Date:10/2/2017)... 2017  Eli Lilly and Company (NYSE: ... third quarter of 2017 on Tuesday, October 24, 2017. ... day with the investment community and media to further ... call will begin at 9 a.m. Eastern time. Investors, ... webcast of the conference call through a link that ...
Breaking Medicine Technology: